Clinical Trial Update: Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluated subcutaneous sarilumab for improving quality of life in people with indolent systemic mastocytosis; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Indolent Systemic Mastocytosis

Drugs mentioned

• KEVZARA (sarilumab)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Indolent Systemic Mastocytosis | Phase 2 | Status: COMPLETED | Results posted: 2024-12-17